The nice people at “The Oncologist” sent their
update today….
 | Practice-Changing Article Trastuzumab Cardiotoxicity in Early Breast Cancer
With
breast cancer patients experiencing longer survival, emphasizing their
overall health through management of late and long‐term treatment
effects is becoming increasingly important. This article reports a
multiregional real‐world population‐based cohort investigation carried
out to compare short‐term and long‐term cardiovascular risk of
symptomatic cardiovascular events in women with localized breast cancer
treated with trastuzumab‐based or standard adjuvant therapy in clinical
practice. |
| | | | |
|---|
| Review Article SELNET Recommendations in Sarcoma During COVID-19 The
COVID‐19 pandemic has caused deferral, modification, or cessation of
treatment for patients with cancer. This article presents a consensus on
prioritizing recommendations across the continuum of sarcoma patient
care. |
| |
|---|
|
|
| Everolimus and Estrogen Deprivation Therapy for Fibrolamellar Carcinoma
Lessons Learned - FLC
is a complex cancer with many implicated oncogenic pathways. Single or
dual targeting does not appear to alter the natural history of the
cancer, and novel therapeutics are needed.
- Estrogen
deprivation therapy with letrozole and leuprolide, alone or in
combination with the mTOR inhibitor, everolimus, did not demonstrate
clinical activity in advanced fibrolamellar carcinoma.
- The study drugs were well tolerated when administered as single agents or in combination in this patient population.
- This
study demonstrates that, despite the rarity of FLC, multicenter
therapeutic clinical trials are feasible and support the value of this
consortium.
|
| |
|---|
|
|
FDA
Approval Summary: Pembrolizumab for Recurrent Locally Advanced or
Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Expressing PD-L1 On
September 22, 2017, the Food and Drug Administration (FDA) granted
accelerated approval to pembrolizumab (KEYTRUDA®, Merck & Co., Inc.)
for the treatment of patients with recurrent, locally advanced or
metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma
with disease progression on or after two or more systemic therapies,
including fluoropyrimidine- and platinum-containing chemotherapy and, if
appropriate, HER2/neu-targeted therapy, and whose tumors express
programmed death-ligand 1 (PD-L1), as determined by an FDA-approved
test.
"I
need to know what makes somebody tick…" - Challenges and strategies of
implementing shared decision-making in individualized oncology This
empirical-ethical study explores factors potentially relevant for
current difficulties to translate the concept of shared decision-making
into clinical practice. |
More CME
No comments:
Post a Comment